GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Pacific Biosciences of California Inc (NAS:PACB) » Definitions » EBIT

Pacific Biosciences of California (Pacific Biosciences of California) EBIT : $-304.1 Mil (TTM As of Dec. 2023)


View and export this data going back to 2010. Start your Free Trial

What is Pacific Biosciences of California EBIT?

Pacific Biosciences of California's earnings before interest and taxes (EBIT) for the three months ended in Dec. 2023 was $-79.2 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was $-304.1 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Pacific Biosciences of California's annualized ROC % for the quarter that ended in Dec. 2023 was -31.10%. Pacific Biosciences of California's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -373.29%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Pacific Biosciences of California's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was -45.15%.


Pacific Biosciences of California EBIT Historical Data

The historical data trend for Pacific Biosciences of California's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pacific Biosciences of California EBIT Chart

Pacific Biosciences of California Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EBIT
Get a 7-Day Free Trial Premium Member Only Premium Member Only -81.52 29.67 -262.34 -299.56 -303.82

Pacific Biosciences of California Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -80.74 -84.54 -66.43 -73.99 -79.17

Competitive Comparison of Pacific Biosciences of California's EBIT

For the Medical Devices subindustry, Pacific Biosciences of California's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Pacific Biosciences of California's EV-to-EBIT Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Pacific Biosciences of California's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Pacific Biosciences of California's EV-to-EBIT falls into.



Pacific Biosciences of California EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-304.1 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pacific Biosciences of California  (NAS:PACB) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Pacific Biosciences of California's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

ROC % (Q: Dec. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Sep. 2023 ) + Invested Capital (Q: Dec. 2023 ))/ count )
=-345.54 * ( 1 - 0.87% )/( (1149.252 + 1053.827)/ 2 )
=-342.533802/1101.5395
=-31.10 %

where

Invested Capital(Q: Sep. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1898.354 - 50.766 - ( 767.789 - max(0, 183.961 - 882.297+767.789))
=1149.252

Invested Capital(Q: Dec. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1746.013 - 60.77 - ( 631.416 - max(0, 95.029 - 742.047+631.416))
=1053.827

Note: The Operating Income data used here is four times the quarterly (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Pacific Biosciences of California's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

ROC (Joel Greenblatt) %(Q: Dec. 2023 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Sep. 2023  Q: Dec. 2023
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=-316.66/( ( (74.95 + max(-59.993, 0)) + (69.025 + max(25.683, 0)) )/ 2 )
=-316.66/( ( 74.95 + 94.708 )/ 2 )
=-316.66/84.829
=-373.29 %

where Working Capital is:

Working Capital(Q: Sep. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(30.486 + 68.256 + 15.766) - (50.766 + 22.372 + 101.363)
=-59.993

Working Capital(Q: Dec. 2023 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(36.615 + 56.676 + 17.34) - (60.77 + 16.342 + 7.836)
=25.683

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Pacific Biosciences of California's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Dec. 2023 )
=-304.127/673.628
=-45.15 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Pacific Biosciences of California EBIT Related Terms

Thank you for viewing the detailed overview of Pacific Biosciences of California's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.


Pacific Biosciences of California (Pacific Biosciences of California) Business Description

Traded in Other Exchanges
Address
1305 O’Brien Drive, Menlo Park, CA, USA, 94025
Pacific Biosciences of California Inc is a biotechnology company focused on the design, development, and commercialization of tools for biological research. The company develops sequencing systems to assist in resolving genetically complex problems. Its sequencing systems provide access to a wide range of applications and are designed for expandable improvements to performance capability. The majority of the company's revenue is derived from North America, followed by Asia and Europe.
Executives
Oene Mark Van officer: Chief Operating Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Christian O Henry director 9885 TOWNE CENTRE DRIVE, SAN DIEGO CA 92121
David W Meline director 3M COMPANY, 3M OFFICE OF GENERAL COUNSEL, ST PAUL MN 55144-1000
Susan G. Kim officer: Chief Financial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Jeff Eidel officer: See Remarks 1305 O'BRIEN DR., MENLO PARK CA 94025
Michele Farmer officer: Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
William W. Ericson director 777 MARINERS ISLAND BOULEVARD, SUITE 550, SAN MATEO CA 94404
Peter Fromen officer: Chief Commercial Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Hannah Valantine director 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Michael Hunkapiller director 400 HAMILTON AVENUE, 4TH FLOOR, PALO ALTO CA 94301
Eric Schaefer officer: VP Chief Accounting Officer 1305 O'BRIEN DRIVE, MENLO PARK CA 94025
Kathy Ordonez director 3 GIRALDA FARMS, C/O QUEST DIAGNOSTICS, MADISON NJ 07940
Randall S Livingston director
Lucy Shapiro director 10210 GENETIC CENTER COURT, SAN DIEGO CA 92121
David Botstein director 1380 WILLOW ROAD, PACIFIC BIOSCIENCES OF CALIFORNIA INC, MENLO PARK CA 94025